The Silverstein Foundation for Parkinson’s with GBA Announces Grant Funding to AcureX Therapeutics
Summary
AcureX has discovered proprietary targets and drugs that reactivate mitophagy in PD patients by stopping improper signaling to the mitochondrial protein Miro1. “With our therapeutic strategy, focused on correcting Miro1 signaling, coupled with the use of Miro1 as a clinical biomarker of drug efficacy, we aim to develop therapies with the potential to stop disease progression.” Jonathan Silverstein, founder of The Silverstein Foundation for Parkinson’s with GBA, added, “The Foundation is committed to supporting the development of innovative therapeutics that leverage genetic insights to treat and reverse the neurodegenerative process in PD. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. The Foundation collaborates with clinicians, scientists, and biotechnology companies to accelerate research and clinical trials in an effort to rapidly bring new disease-modifying therapeutic options to patients. The Foundation applies a unique flexible funding model including both new company formation and traditional research grants to deliver in real-time on its mission of rapidly developing novel disease-modifying treatments for Parkinson’s disease.